Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and University College London have come together to form CASMI - the Centre for the Advancement of Sustainable Medical Innovation.

Under the joint Chairmanship of Sir John Bell, Regius Professor of Medicine at Oxford and Sir John Tooke, UCL Vice Provost (Health) and led by founding Director, Dr Richard Barker, CASMI seeks to address one of the most important societal problems of the 21st century – turning investment in basic research into population health gain. An official launch event to mark this unique commitment by two world-leading Universities is being held at the Wellcome Trust today.

CASMI is a virtual Centre, which brings together CASMI Fellows across the partner Universities, from disciplinary areas including life and biomedical science, ethics, laws, economics, statistics, politics, business studies, psychology, sociology, behavioural science and more. This enables the Centre to bring a uniquely holistic perspective on the core problem that CASMI will tackle - turning bioscience breakthroughs into patient benefit. This challenge is also a specific area of national priority, as addressed by the Government’s Strategy for UK Life Sciences.

Dr Richard Barker, CASMI Director said: “We will deliver a unique holistic approach to tackling what’s known as the three main ‘gaps in translation’ – i) breakthroughs in the lab not producing therapies for trial; ii) too many products failing to overcome the hurdles of regulatory approval and reimbursement; and iii) approved products not being used effectively to deliver patient benefit. We will bring together the breadth of academic disciplines across UCL, Oxford and beyond to develop ‘testable models’, such as the Adaptive Licensing project already in train, supported by the Wellcome Trust.”

"Improving the productivity of medical innovation and the speed with which scientific advances are translated into new treatments is critical for the future of UK life sciences. It's our goal that CASMI plays a leading role in this arena," said CASMI Co-Chair Sir John Bell.

CASMI Co-Chair, Professor Sir John Tooke commented that “Drawing on the capacities of two world-class universities and our wider partnerships, CASMI offers the opportunity to rise to the challenge of reshaping the innovation pipeline for the benefit of both patients and the economy.”

Further details about CASMI are available on the website at www.casmi.org.uk

Similar stories

Reducing fat in the diabetic heart could improve recovery from heart attack

New research from the Department of Physiology, Anatomy and Genetics has shown that in type 2 diabetes an overload of lipids reduces the heart’s ability to generate energy during a heart attack, decreasing chances of recovery.

Brain cortex may regulate the need for sleep

Why we sleep, and the processes behind sleep, are amongst the most interesting questions in modern neuroscience.

New data show rise in hospital admissions for unvaccinated pregnant women

The Chief Midwifery Officer for England will urge expectant mums to have their COVID-19 vaccination as soon as possible. This follows a worrying rise in unvaccinated women being admitted to hospital with severe COVID-19, and evidence that the Delta variant poses a significantly greater risk than all previous strains.

Cooking with coal or wood associated with increased risk of major eye diseases

A study involving nearly half a million people in China reveals a clear link between cooking with wood or coal, and an increased risk of major eye diseases that can lead to blindness, according to a report published today in PLOS Medicine.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.